Mixed messages surrounding their clinical benefits threatened the legitimacy of stem cell therapies for multiple sclerosis, but there is still plenty of promise.
Explore how emerging in vitro systems — built from primary cells, cocultures, and vascularized tissues — are improving translational research outcomes.